News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
291,288 Results
Type
Article (15469)
Company Profile (227)
Press Release (275585)
Multimedia
Podcasts (111)
Webinars (12)
Section
Business (90652)
Career Advice (168)
Deals (13466)
Drug Delivery (51)
Drug Development (50951)
Employer Resources (31)
FDA (5959)
Job Trends (5201)
News (145663)
Policy (10087)
Tag
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (1)
2027 Genetown Standard (4)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (957)
Accelerated approval (34)
ADA (33)
Adcomms (16)
Allergies (118)
Alliances (21764)
ALS (178)
Alzheimer's disease (1204)
Antibody-drug conjugate (ADC) (454)
Approvals (6297)
Artificial intelligence (407)
ASCO (221)
Autoimmune disease (303)
Automation (16)
Bankruptcy (108)
Best Places to Work (4558)
BIO (54)
BIOSECURE Act (6)
Biosimilars (139)
BioSpace Insights (71)
Biotechnology (176)
Bladder cancer (128)
Brain cancer (59)
Breast cancer (452)
Cancer (4334)
Cardiovascular disease (323)
Career advice (161)
Career pathing (13)
CAR-T (300)
CDC (8)
Celiac Disease (1)
Cell therapy (789)
Cervical cancer (25)
Clinical research (45532)
Collaboration (1586)
Commercialization (4)
Company closure (3)
Compensation (850)
Complete response letters (68)
COVID-19 (1134)
CRISPR (116)
C-suite (875)
Cystic fibrosis (125)
Data (6295)
Denatured (23)
Depression (127)
Dermatology (73)
Diabetes (356)
Diagnostics (1503)
Digital health (19)
Diversity (6)
Diversity, equity & inclusion (9)
Drug discovery (313)
Drug pricing (54)
Drug shortages (3)
Duchenne muscular dystrophy (311)
Earnings (33305)
Editorial (36)
Employer branding (4)
Employer resources (29)
Events (53993)
Executive appointments (746)
FDA (8394)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (24)
Frontotemporal dementia (32)
Funding (1320)
Gene editing (241)
Generative AI (41)
Gene therapy (646)
GLP-1 (587)
Government (1194)
Grass and pollen (3)
Guidances (179)
Healthcare (6743)
Hematology (118)
HIV (31)
Huntington's disease (61)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (102)
Immunology and inflammation (260)
Immuno-oncology (88)
Indications (152)
Infectious disease (1299)
Inflammatory bowel disease (188)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (231)
Interviews (20)
IPO (7401)
IRA (13)
Job creations (870)
Job search strategy (135)
JPM (41)
Kidney cancer (11)
Labor market (36)
Layoffs (267)
Leadership (15)
Legal (1403)
Licensing (9)
Liver cancer (48)
Longevity (26)
Lung cancer (577)
Lymphoma (334)
Machine learning (35)
Management (7)
Manufacturing (589)
Marketing (9)
MASH (170)
Medical affairs (1)
Medical device (2731)
Medtech (2767)
Mergers & acquisitions (6876)
Metabolic disorders (985)
mRNA (180)
Multiple sclerosis (133)
NASH (14)
Neurodegenerative disease (376)
Neuropsychiatric disorders (92)
Neuroscience (2513)
Neurotech (1)
NextGen: Class of 2026 (2040)
Non-profit (887)
Now hiring (42)
Obesity (437)
Opinion (146)
Ovarian cancer (199)
Pain (144)
Pancreatic cancer (258)
Parkinson's disease (330)
Partnered (14)
Patents (437)
Patient recruitment (620)
Peanut (51)
People (27512)
Pharmaceutical (29)
Pharmacy benefit managers (6)
Phase 1 (16131)
Phase 2 (21177)
Phase 3 (13367)
Pipeline (7131)
Policy (108)
Postmarket research (853)
Preclinical (6818)
Press Release (30)
Prostate cancer (218)
Psychedelics (74)
Radiopharmaceuticals (301)
Rare diseases (998)
Real estate (1459)
Recruiting (12)
Regulatory (10935)
Reports (24)
Research institute (998)
Resumes & cover letters (20)
Rett syndrome (42)
RNA editing (31)
RSV (25)
Schizophrenia (157)
Series A (257)
Series B (183)
Service/supplier (1)
Sickle cell disease (98)
Special edition (21)
Spinal muscular atrophy (127)
Sponsored (17)
Startups (2037)
State (1)
Stomach cancer (5)
Supply chain (42)
Tariffs (19)
The Weekly (86)
Vaccines (423)
Venture capital (98)
Weight loss (233)
Women's health (50)
Worklife (2)
Date
Last 7 days (397)
Last 30 days (1397)
Last 365 days (18006)
2026 (11450)
2025 (18098)
2024 (20467)
2023 (22414)
2022 (26811)
2021 (27803)
2020 (23356)
2019 (16226)
2018 (11739)
2017 (13744)
2016 (11841)
2015 (14353)
2014 (10392)
2013 (7483)
2012 (7534)
2011 (7614)
2010 (7430)
Location
Africa (156)
Alabama (79)
Alaska (2)
Arizona (92)
Arkansas (6)
Asia (18905)
Australia (3242)
California (9232)
Canada (2335)
China (1141)
Colorado (330)
Connecticut (345)
Delaware (317)
Europe (40604)
Florida (1209)
Georgia (267)
Hawaii (3)
Idaho (18)
Illinois (563)
India (57)
Indiana (220)
Iowa (9)
Japan (341)
Kansas (89)
Kentucky (11)
Louisiana (17)
Maine (14)
Maryland (944)
Massachusetts (7359)
Michigan (131)
Minnesota (325)
Mississippi (3)
Missouri (38)
Montana (17)
Nebraska (6)
Nevada (51)
New Hampshire (22)
New Jersey (2090)
New Mexico (13)
New York (2286)
North Carolina (1074)
North Dakota (7)
Northern California (4723)
Ohio (230)
Oklahoma (11)
Oregon (25)
Pennsylvania (1685)
Puerto Rico (12)
Rhode Island (26)
South America (216)
South Carolina (13)
Southern California (3730)
Tennessee (62)
Texas (1274)
United States (30487)
Utah (128)
Virginia (185)
Washington D.C. (37)
Washington State (754)
West Virginia (1)
Wisconsin (66)
291,288 Results for "karuna therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
May 28, 2026
·
4 min read
Deals
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio.
March 18, 2024
·
8 min read
Deals
Bristol Myers Squibb Completes Acquisition of PureTech’s Founded Entity Karuna Therapeutics for $14 Billion
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, today announced the completed acquisition of its Founded Entity, Karuna Therapeutics, Inc. (“Karuna”), by Bristol Myers Squibb (NYSE: BMY) (“BMS”), which has acquired all outstanding common stock of Karuna for $330.00 per share, for a total equity value of approximately $14 billion.
March 18, 2024
·
13 min read
Deals
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
Bristol Myers Squibb and Karuna Therapeutics, Inc. announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
December 22, 2023
·
17 min read
Genetown
Karuna Therapeutics to Present at Upcoming September 2023 Investor Conferences
Karuna Therapeutics, Inc. announced that management will present at the following upcoming investor conferences.
August 30, 2023
·
1 min read
Drug Development
BMS Sees Early ROI for $14B Karuna Buy with Phase III Schizophrenia Win
Fresh off of its $14 billion acquisition of Karuna Therapeutics, Bristol Myers Squibb on Saturday reported promising late-stage data for Karuna’s antipsychotic KarXT, which elicited significant symptomatic improvement in schizophrenia symptoms.
April 8, 2024
·
2 min read
·
Tristan Manalac
Genetown
Karuna Therapeutics to Present at Upcoming November 2023 Investor Conferences
Karuna Therapeutics, Inc., a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that management will present at the following upcoming investor conferences.
November 1, 2023
·
1 min read
Business
Karuna Therapeutics Announces Leadership Appointments - August 03, 2023
Karuna Therapeutics, Inc. announced the appointment of Jonathan Rosin to Chief Human Resources Officer and the promotion of Jason Brown to Chief Financial Officer.
August 3, 2023
·
4 min read
Genetown
Karuna Therapeutics to Present at Upcoming May 2023 Investor Conferences
Karuna Therapeutics, Inc. announced that management will present at the following upcoming investor conferences.
May 2, 2023
·
1 min read
Business
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a general business update.
February 22, 2024
·
11 min read
1 of 29,129
Next
